-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $8.25

Benzinga·12/10/2025 10:29:21
Listen to the news
Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and raises the price target from $8 to $8.25.